Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:21 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis)
NCT03579966 · Catalyst Pharmaceuticals, Inc. · PHASE3 · terminated · last registry update 2024-05-07 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Lack of measure appropriate data (MG-ADL).” | – | Registry record, Catalyst Pharmaceuticals, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against KCNQ1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-05-06Results posted on the registry: Vanderbilt University Medical Center, Guanfacine + Placebo (NCT04742673)
- 2025-04-13Results posted on the registry: Alliance for Clinical Trials in Oncology, metformin hydrochloride (NCT01905046)
- 2025-03-26Phase 3 first posted: Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh, Metformin with Semaglutide (NCT06896981)
- 2025-02-03Results posted on the registry: Medical University of South Carolina, Metformin (NCT02946996)
- 2025-01-08Phase 3 first posted: City of Hope Medical Center, Extended Release Metformin Hydrochloride (NCT06763328)
- 2024-10-16Results posted on the registry: Vanderbilt University Medical Center, Metformin + Placebo (NCT03617458)
- 2024-08-26Phase 3 first posted: Celltrion, CT-L03 Group 1 + CT-L03 Group 2 (NCT06571591)
- 2024-07-05Phase 3 first posted: Rush University Medical Center, Chlorhexidine + Gentamicin (NCT06489431)
- 2024-06-11Phase 3 first posted: Amsterdam UMC, Metformin Hydrochloride + Placebo (NCT06452498)
- 2024-05-08Phase 3 first posted: Beni-Suef University, Metformin + Dapagliflozin (NCT06405178)
- 2024-05-01Results posted on the registry: Massachusetts General Hospital, Glipizide + Metformin (NCT01762046)
- 2024-01-30Phase 3 first posted: Mostafa Bahaa, Celecoxib 200mg + Metformin (NCT06231758)
- 2024-01-29Phase 3 first posted: Ain Shams University, Green Tea Leaf Extract Decaffeinated + Metformin Hydrochloride 500 MG (NCT06229795)
- 2023-11-18Phase 3 first posted: MGH Institute of Health Professions, Dalfampridine 10 MG [Ampyra] (NCT06136728)
- 2023-11-02Phase 3 first posted: University of Utah, a drug against KCNQ1 (NCT06112990)
- 2023-10-10Results posted on the registry: Janssen Research & Development, LLC, Erdafitinib + Midazolam (NCT02365597)
- 2023-09-13Phase 3 first posted: Lina Bergman, Metformin ER + Placebo (NCT06033131)
- 2023-07-28Phase 3 first posted: Beni-Suef University, liraglutide + Metformin (NCT05965908)
- 2023-07-13Results posted on the registry: University of Minnesota, Metformin + Placebo (NCT04510194)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision